# Retatrutide References: Full Citation List with DOIs and PubMed Links

> Complete references for the retatrutide research literature cited on this site — Phase 1b, Phase 2 obesity/diabetes/MASLD trials, cryo-EM structure, and systematic reviews. DOIs and PubMed URLs included.

Every citation used on this site, with DOIs and PubMed / PMC URLs.

## Full citation list

All citations used across this site are listed below with full bibliographic details. DOIs link to the publisher record; PubMed/PMC URLs link to the indexed abstract or open-access full text where available.

## References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
[2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/
[3] Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/
[4] Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/
[5] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/
[6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
[7] Madsbad S, et al. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs. 2025;34(3):197-215. https://doi.org/10.1080/13543784.2025.2472408
[8] Melson E, et al. What is the pipeline for future medications for obesity? International Journal of Obesity. 2025;49(3):433-451. https://doi.org/10.1038/s41366-024-01473-y
[9] Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj Metabolic Health and Disease. 2024;2(1):31. https://doi.org/10.1038/s44324-024-00030-5
[10] Deravi M, et al. The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. Journal of Pharmacy Technology. 2024;40(6):300-305. https://doi.org/10.1177/87551225241285326
[11] Cooper ME, et al. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. Journal of Clinical Investigation. 2025;135(21):e194749. https://doi.org/10.1172/JCI194749
[12] Takrori E, et al. Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. Medicina (Kaunas). 2025. https://doi.org/10.3390/medicina61111987
[13] Cho YK, et al. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. Clinical and Molecular Hepatology. 2026. https://doi.org/10.3350/cmh.2025.0744
[14] Muzurović E, et al. Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism: Clinical and Experimental. 2026. https://doi.org/10.1016/j.metabol.2026.156494

---

A no-vendor reading of the retatrutide trial record — Phase 2 numbers read straight from the source, Phase 3 gaps named as gaps, and nothing here scripted, dispensed, or sold.